On the other hand, Di Buduo et al[17] highlighted the importance of TPO-RAs in the treatment of ITP, emphasizing their role in both combination and single-agent therapies through the activation of the AKT and ERK1/2 signaling pathways. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.